FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296252912> ?p ?o ?g. }

• W4296252912 endingPage "4491" @default.
• W4296252912 startingPage "4491" @default.
• W4296252912 abstract "Cutaneous T cell lymphoma (CTCL) is a group of non-Hodgkin's primary cutaneous T cell lymphomas, with Mycosis Fungoides and Sézary syndrome (SS) being the two most common subtypes. Fatty acid synthase (FASN) is a crucial enzyme that catalyses the biosynthesis of fatty acids, which has been reported to play an oncogenic role in various malignancies but not in CTCL so far. Herein, we show that FASN is highly expressed in CTCL cell lines and in peripheral blood mononuclear cells (PBMCs) from CTCL patients, while it is not in PBMCs from healthy individuals. The inhibition of FASN in CTCL cell lines impairs cell viability, survival, and proliferation, but, interestingly, it also increases FASN expression. However, inhibiting sterol regulatory element binding protein (SREBP), a transcription factor that promotes the expression of FASN, partially reversed the upregulation of FASN induced by FASN inhibitors. Thus, the combination of FASN and SREBP inhibitors enhanced the effects on both CTCL cell lines and PBMCs from SS patients, where a valid inhibition on cell proliferation could be verified. Importantly, compared to non-malignant cells, primary malignant cells are more sensitive to the inhibition of FASN and SREBP, making the combination of FASN and SREBP inhibitors a promising novel therapeutic strategy in CTCL." @default.
• W4296252912 created "2022-09-19" @default.
• W4296252912 creator A5004078001 @default.
• W4296252912 creator A5018643002 @default.
• W4296252912 creator A5023086225 @default.
• W4296252912 creator A5028590821 @default.
• W4296252912 creator A5028850948 @default.
• W4296252912 creator A5033984309 @default.
• W4296252912 creator A5038140471 @default.
• W4296252912 creator A5046439692 @default.
• W4296252912 creator A5056937217 @default.
• W4296252912 creator A5059570455 @default.
• W4296252912 creator A5059586969 @default.
• W4296252912 creator A5065084278 @default.
• W4296252912 creator A5067045121 @default.
• W4296252912 date "2022-09-16" @default.
• W4296252912 modified "2023-09-30" @default.
• W4296252912 title "Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL" @default.
• W4296252912 cites W1501481238 @default.
• W4296252912 cites W1893502830 @default.
• W4296252912 cites W1905915630 @default.
• W4296252912 cites W1938733549 @default.
• W4296252912 cites W1965671023 @default.
• W4296252912 cites W1966380360 @default.
• W4296252912 cites W1972600852 @default.
• W4296252912 cites W1982541197 @default.
• W4296252912 cites W1982892081 @default.
• W4296252912 cites W1986234170 @default.
• W4296252912 cites W1987231965 @default.
• W4296252912 cites W1999816037 @default.
• W4296252912 cites W2002822759 @default.
• W4296252912 cites W2013251233 @default.
• W4296252912 cites W2039163595 @default.
• W4296252912 cites W2040482137 @default.
• W4296252912 cites W2042605361 @default.
• W4296252912 cites W2051830269 @default.
• W4296252912 cites W2059010575 @default.
• W4296252912 cites W2067872596 @default.
• W4296252912 cites W2077548113 @default.
• W4296252912 cites W2086453930 @default.
• W4296252912 cites W2090308692 @default.
• W4296252912 cites W2102322990 @default.
• W4296252912 cites W2102979437 @default.
• W4296252912 cites W2107454005 @default.
• W4296252912 cites W2116516144 @default.
• W4296252912 cites W2117692326 @default.
• W4296252912 cites W2123037292 @default.
• W4296252912 cites W2130844401 @default.
• W4296252912 cites W2135805794 @default.
• W4296252912 cites W2137584993 @default.
• W4296252912 cites W2145408950 @default.
• W4296252912 cites W2148378558 @default.
• W4296252912 cites W2153178365 @default.
• W4296252912 cites W2156949267 @default.
• W4296252912 cites W2171874512 @default.
• W4296252912 cites W2275155656 @default.
• W4296252912 cites W2324023748 @default.
• W4296252912 cites W2467842752 @default.
• W4296252912 cites W2523687917 @default.
• W4296252912 cites W2529703021 @default.
• W4296252912 cites W2580015445 @default.
• W4296252912 cites W2755306738 @default.
• W4296252912 cites W2805393256 @default.
• W4296252912 cites W2889602315 @default.
• W4296252912 cites W2909964376 @default.
• W4296252912 cites W2910438485 @default.
• W4296252912 cites W2925521234 @default.
• W4296252912 cites W2975394703 @default.
• W4296252912 cites W2992324722 @default.
• W4296252912 cites W3036162258 @default.
• W4296252912 cites W3082755785 @default.
• W4296252912 cites W3083571783 @default.
• W4296252912 cites W3091953196 @default.
• W4296252912 cites W3100015901 @default.
• W4296252912 cites W3126915679 @default.
• W4296252912 doi "https://doi.org/10.3390/cancers14184491" @default.
• W4296252912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36139650" @default.
• W4296252912 hasPublicationYear "2022" @default.
• W4296252912 type Work @default.
• W4296252912 citedByCount "2" @default.
• W4296252912 countsByYear W42962529122023 @default.
• W4296252912 crossrefType "journal-article" @default.
• W4296252912 hasAuthorship W4296252912A5004078001 @default.
• W4296252912 hasAuthorship W4296252912A5018643002 @default.
• W4296252912 hasAuthorship W4296252912A5023086225 @default.
• W4296252912 hasAuthorship W4296252912A5028590821 @default.
• W4296252912 hasAuthorship W4296252912A5028850948 @default.
• W4296252912 hasAuthorship W4296252912A5033984309 @default.
• W4296252912 hasAuthorship W4296252912A5038140471 @default.
• W4296252912 hasAuthorship W4296252912A5046439692 @default.
• W4296252912 hasAuthorship W4296252912A5056937217 @default.
• W4296252912 hasAuthorship W4296252912A5059570455 @default.
• W4296252912 hasAuthorship W4296252912A5059586969 @default.
• W4296252912 hasAuthorship W4296252912A5065084278 @default.
• W4296252912 hasAuthorship W4296252912A5067045121 @default.
• W4296252912 hasBestOaLocation W42962529121 @default.
• W4296252912 hasConcept C104317684 @default.
• W4296252912 hasConcept C126322002 @default.

• next